Sorrento Therapeutics Inc logo

Sorrento Therapeutics Inc

1
OTCPK:SRNE (USA)  
$ 0.01 -0.0063 (-31.5%) 10:08 PM EST
At Loss
P/B:
0
Market Cap:
$ 7.55M
Enterprise V:
$ 134.52M
Volume:
54.42K
Avg Vol (2M):
211.30K
Warning! GuruFocus detected 5 Severe warning signs with SRNE. Try a 7-Day Free Trial to check it out.
Also Trade In:
Volume:
54.42K
Market Cap $:
7.55M
At Loss
Avg Vol (2M):
211.30K
Enterprise Value $:
134.52M
PB Ratio:
0
Alerts Website SEC Filings Stock PDF
Dataset
Financial Download Manual of Stocks™

Sorrento Therapeutics Inc (OTCPK:SRNE) Stock News, Headlines & Updates

Sorrento Therapeutics Inc Stock News from GuruFocus

Total 293
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 8
Feb 15, 2024
Sorrento Therapeutics Inc Annual Shareholders Meeting Transcript
GuruFocus Research • 10:18pm
Sorrento Therapeutics Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
GuruFocus Research • 10:18pm
Sorrento Therapeutics COVID-19 Pipeline Update, R&D Discussion and Management Q&A Transcript
GuruFocus Research • 10:18pm
Sep 12, 2023
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Marketwired • 8:00am
Sep 07, 2023
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Marketwired • 8:00am
Aug 08, 2023
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
PRNewswire • 9:00am
Jul 27, 2023
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
Marketwired • 8:00am
Jul 05, 2023
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Marketwired • 8:00am
Jun 26, 2023
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Marketwired • 8:00am
Feb 19, 2023
Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")
sperokesalga • 8:00pm
Feb 17, 2023
Sorrento Issues Update to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")
sperokesalga • 3:00pm
Feb 13, 2023
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
sperokesalga • 3:00pm
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
sperokesalga • 6:00pm
Feb 05, 2023
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
Stock market mentor • 10:00pm
Jan 09, 2023
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Stock market mentor • 8:00am
Dec 05, 2022
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
Value_Insider • 3:00pm
Nov 29, 2022
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir B
Value_Insider • 2:00pm
Nov 13, 2022
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
Value_Insider • 3:00pm
Nov 10, 2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), Debuts on Nasdaq Under Ticker "SCLX"
Value_Insider • 2:00pm
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
Value_Insider • 2:00pm
Oct 31, 2022
Scilex Holding Company ("Scilex"), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, "Sorrento"), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4
Value_Insider • 8:00am
Oct 14, 2022
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)
Value_Insider • 2:00pm
Aug 31, 2022
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Ds*** • 11:00pm
Aug 23, 2022
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
PurpleRose • 8:00am
Aug 19, 2022
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
PurpleRose • 8:00am
Aug 17, 2022
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa
PurpleRose • 8:00am
Aug 03, 2022
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
PurpleRose • 8:00am
Jul 15, 2022
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
PurpleRose • 2:41pm
Jul 14, 2022
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
PurpleRose • 3:36pm
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
PurpleRose • 10:28am
Jul 13, 2022
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
PurpleRose • 10:22am
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
PurpleRose • 8:40am
Jul 07, 2022
Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.
GuruFocusNews • 8:44am
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors
GuruFocusNews • 8:12am
Jul 05, 2022
Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
GuruFocusNews • 2:36pm
Jul 04, 2022
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
GuruFocusNews • 3:31pm
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
GuruFocusNews • 10:27am
Jul 03, 2022
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
GuruFocusNews • 9:23am
Jul 01, 2022
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 20
GuruFocusNews • 8:21am
Jun 30, 2022
Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia
GuruFocusNews • 10:05am
Total 293
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 8
Show
Entries

Headlines

Total 0
  • 1
No recent news
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.